Rituximab in myasthenia gravis: a “to be or not to be” inhibitor of T cell function

E-ISSN： 1749-6632|1413|1|41-48

ISSN： 0077-8923

Source： ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol.1413, Iss.1, 2018-02, pp. : 41-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A unique subphenotype of myasthenia gravis

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 1412, Iss. 1, 2018-01 ,pp. : 14-20

John Wiley & Sons Inc

Access to resources Recommend Favorite

An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor–positive myasthenia gravis patients

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 1413, Iss. 1, 2018-02 ,pp. : 154-162

John Wiley & Sons Inc

Access to resources Recommend Favorite

Developing treatment guidelines for myasthenia gravis

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 1412, Iss. 1, 2018-01 ,pp. : 95-101

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 1412, Iss. 1, 2018-01 ,pp. : 154-165

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serological and experimental studies in different forms of myasthenia gravis

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol. 1413, Iss. 1, 2018-02 ,pp. : 143-153

John Wiley & Sons Inc

Access to resources Recommend Favorite